A best evidence topic (BET) in cardiac surgery was written according to a structured protocol. The question addressed was whether ABOincompatible (ABO-I) heart transplant recipients have a similar survival rate as an ABO-compatible (ABO-C) transplant in the pediatric population -1 year of age. Altogether more than 112 papers were found using the reported search, of which 10 represented the best evidence to answer the clinical question. Generally, ABO-I transplantation has been associated with the neonatal population because of the relative immaturity of the immune system for the first year of life. In the BET the search-term 'pediatric' was used as a method to ensure retrieval all relevant papers. However, the vast majority of the patients reviewed were -1 year of age with specific techniques undertaken to modulate preoperative, intraoperative and postoperative isohemagglutinin titer levels with rejection monitoring. Therefore, the BET conclusions should not be applied to the pediatric group as a broad age classification. Two large series are of particular interest. Patel et al. reviewed all primary heart transplantation recipients F1 year of age in the United Network for Organ SharingyOrgan Procurement and Transplantation Network (UNOSyOPTN) registry (ABO-Is35 vs. ABO-Cs556). There was no difference in 30-day mortality (ABO-Is5.9% vs. ABO-Cs8.8%; Ps0.55); one-year mortality (ABO-Is16.6% vs. ABO-Cs14.7%; Ps0.77); graft rejection (ABO-Is1 vs. ABOCs0); and graft failure (ABO-Is24% vs. ABO-Cs24%; P)0.99). Three-year Kaplan-Meier survival was 70% (Ps0.85). Propensity score adjusted analysis did not implicate ABO-I as a predictor of mortality whazard ratio (HR)s3.6, confidence interval (CI): 0.2-49.0; Ps0.33x. The ABO-I group demonstrated an increased need for pacemaker (ABO-Is3.1% vs. ABO-Cs0.4%; Ps0.03) and higher stroke rate (ABOIs12.9% vs. ABO-Cs1.3%; P-0.0001). Dipchand et al. published the results of the Toronto cohort from 1992 to 2006 (ABO-Is16 vs. ABOCs38). The median age at transplantation (ABO-Is88 days vs. ABO-Cs84 days; Ps0.82) and the number of neonatal transplant recipients (ABO-Is17% vs. ABO-Cs22%; Ps0.59) was similar. The freedom from post-transplantation death or retransplantation was equivalent at one year (ABO-Is77% vs. ABO-Cs84%) and seven years (ABO-Is74% vs. Ps0.87). No significant difference was observed for the five-year freedom from: rejection (ABO-Is60% vs. ABO-Cs45%; Ps0.41); renal dysfunction (ABO-Is67% vs. ABO-Cs72%; Ps0.70); allograft vasculopathy (ABO-Is87% vs. ABO-Cs78%; Ps0.45); and post-transplantation lymphoproliferative disorder (PTLD) (ABO-Is87% vs. Ps0.93). We conclude that ABO-I transplantation is comparable to ABO-C transplantation, with several retrospective papers concluding there is no difference in mortality, morbidity or graft failure in the pediatric population -1 year of age.
Introduction
A best evidence topic (BET) was constructed according to a structured protocol. This is fully described in the ICVTS w1x.
Three-part question
In wpediatric patients undergoing heart transplantationx does wABO-compatible or ABO-incompatible donor organx result in equivalent wsurvivalx.
Clinical scenario
A 14-day-old neonate, ABO-blood type Oq, with dilated cardiomyopathy (DCM) has required extracorporeal *Corresponding author. Tel.: q1 778 987 5080; fax: q1 604 520 4899. E-mail address: richard.saczkowski@gmail.com (R. Saczkowski). membrane oxygenation (ECMO) for the past 10 days with no myocardial recovery. An ABO-incompatible (ABO-I) (type Aq) donor organ becomes available. As the consultant transplant surgeon you decide to review the literature prior to speaking with the parents regarding a potential donor heart. You specifically want to know if there is a survival difference between ABO-I and ABO-compatible (ABO-C) heart transplantation.
Search strategy
Medline 1950-November 2009 using Pubmed interface w'ABO Blood-Group System' (MeSH)x AND w'Heart Transplantation' (MeSH)x.
Search outcome
One hundred and twelve papers were found using the reported search. From these, 10 papers were identified that provided the best evidence to answer the question. These are presented in Table 1 .
Results
Patel et al. w2x retrospectively reviewed all infant primary heart transplantation records entered into the United Network for Organ SharingyOrgan Procurement and Transplantation Network (UNOSyOPTN) registry between January 1999 and January 2007. There were 35 and 556, ABO-I and ABO-C transplants, respectively. There was no difference in 30-day mortality (ABO-Is5.9% vs. Ps0.55) and one-year post-transplantation mortality (ABO-Is16.6% vs. Ps0.77) . Both groups had Kaplan-Meier survival at three years approaching 70% (Ps0.85). Graft rejection rate was low (ABO-Is1 vs. ABO-Cs0) and the incidence of graft failure was equivalent for both groups (ABO-Is24% vs. ABO-Cs24%; P)0.99). The postoperative data were similar for both groups except for an increased need for pacemaker wABO-Is1 (3.1%) vs. ABO-Cs2 (0.4%); Ps0.03x and higher stroke rate wABO-Is4 (12.9%) vs. ABOCs7 (1.3%); P-0.0001x in the ABO-I group. Propensity score adjusted analysis did not implicate ABO-I as a predictor of mortality whazard ratio (HR)s3.6, confidence interval (CI): 0. (1992 -1999 Group IIs53 (2000 x. Group II incorporated the aggressive use of mechanical circulatory support, priority transplant listing and ABO-I transplantation. The median follow-up length for the five ABO-I patients was five months (range: 2-20 months) with no deaths or graft rejection. The reported survival to hospital discharge was 63% and 87% for Group I and Group II, respectively (P-0.05).
West et al. w5x reviewed 20 transplant recipients between 1996 and 2000. Ten patients in the ABO-I group had a median age at transplantation of two months (range: 4 h-14 months) and the ABO-C group median age was 5.5 months (range: 5 weeks-12 months). The median age at last follow-up of the ABO-I and ABO-C survivors was 2.7 years (range: 1.1-4.7 years) and 2.1 years (range: 1-3.4 years), respectively. There was no graft rejection in either group and the authors observed no increased morbidity associated with ABO-I transplantation. According to the authors, both mortalities (ABO-Is2 vs. ABO-Cs0) were not related to ABO-incompatibility, since the grafts demonstrated mild or no evidence of humoral rejection. The implementation of ABO-I transplantation option dramatically reduced the wait-list death rate (58-7%).
Rao et al. w6x retrospectively reviewed five patients considered for ABO-I transplantation since January 2000. Excessive isohemagglutinin titers mandated ABO-C transplantation in two patients. The ages at transplantation of the ABO-I patients were 3, 2 and 21 months and ABO-C recipients were 31 and 18 months. There was no graft rejection, morbidity or mortality reported in either group. The median age of follow-up was 26 months (range: 12-40 months) and 33 months (range: 30-37 months) for the ABO-I and ABO-C, respectively.
Daebritz et al. w7x reported a retrospective review of three ABO-I transplant recipients since December 2004. The age at transplant was 7, 5 and 3.4 months. One patient required long-term dialysis. No other morbidity was reported. There was no graft rejection or mortality after a median follow-up of 16 months (range: 12-17 months).
Schmoeckel et al. w8x reported the retrospective results of two ABO-I transplanted infants since September 2004. The age at transplantation was seven and five months. There was no graft rejection or mortality at time of manuscript submission. One patient required long-term dialysis.
West et al. w9x undertook a competing-risk model analysis of the Toronto ABO-I cohort from 1992 to 2002. The ABO-I and ABO-C groups had 16 and 38 patients, respectively. The analysis demonstrated that ABO-I was a risk factor for wait-list transplantation (P-0.001) and wait-list death (Ps0.002). Time-related estimates showed no statistically significant difference between ABO-I and ABO-C transplant groups in freedom from retransplantation and death after transplantation at four years (ABO-Is74% vs. ABO-Cs72%; Ps0.72). Furthermore, ABO-I transplantation was analyzed as a time-related risk factor for freedom of composite outcome and was found to be not statistically significant at five years (70%) and eight years (67%) (Ps0.81).
Dipchand et al. w10x published the third paper analyzing the Toronto cohort from 1992 to 2006 (ABO-Is16 vs. ABOCs38). The median age at transplantation (ABO-Is88 days vs. ABO-Cs84 days; Ps0.82) and the number of neonatal transplant recipients (ABO-Is17% vs. ABO-Cs22%; Ps0.59) were similar. The freedom from post-transplantation death or retransplantation was equivalent at one year (ABOIs77% vs. ABO-Cs84%) and seven years (ABO-Is74% vs. Ps0.87) . No significant difference was observed for the five-year freedom from: rejection (ABOIs60% vs. ABO-Cs45%; Ps0.41); renal dysfunction (ABOIs67% vs. ABO-Cs72%; Ps0.70); allograft vasculopathy (ABO-Is87% vs. ABO-Cs78%; Ps0.45); and post-transplantation lymphoproliferative disorder (PTLD) (ABO-Is87% vs. Ps0.93) . Also, the median time to first rejection was similar between groups (ABO-Is0.15 years vs. ABO-Cs0.19 years; Ps0.33).
Clinical bottom line
ABO-I transplantation is comparable to ABO-C transplantation, with several retrospective papers concluding there is no difference in mortality in the pediatric population -1 year of age. The frequency of graft failure and associated morbidity are also reported at similar rates between 
